Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive

Frankie Fattorini

Tue, July 7, 2026 astatine 11:52 AM CDT 1 min read

Following multibillion dollar plus acquisitions and artificial quality (AI)-centred deals, Servier's caput of concern improvement outlines however 1 of France's starring pharma companies is readying for the aboriginal amidst a changing geopolitical scene.

In 2026, Servier completed the $2.5 cardinal acquisition of the oncology developer Day One Biopharmaceuticals and acquired the muscular dystrophy concern of Edgewise Therapeutics for astir $2.65 billion, pursuing large AI-focused deals with InSilico Medicine and Iktos. In this latest episode, Pharmaceutical Technology newsman Frankie Fattorini speaks with the caput of concern improvement Frederic Scaerou to recognize however these deals are shaping Servier arsenic the French multinational navigates shifting planetary manufacture trends.

"Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive" was primitively created and published by Pharmaceutical Technology, a GlobalData owned brand.